Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Revenue (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Revenue for 10 consecutive years, with $98000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Revenue fell 50.51% year-over-year to $98000.0, compared with a TTM value of $384000.0 through Dec 2025, down 23.66%, and an annual FY2025 reading of $570000.0, up 13.77% over the prior year.
  • Revenue was $98000.0 for Q2 2025 at VYNE Therapeutics, down from $202000.0 in the prior quarter.
  • Across five years, Revenue topped out at $295000.0 in Q2 2021 and bottomed at $29000.0 in Q4 2022.
  • Average Revenue over 5 years is $147666.7, with a median of $129500.0 recorded in 2021.
  • The sharpest move saw Revenue plummeted 97.48% in 2021, then soared 162.07% in 2023.
  • Year by year, Revenue stood at $273000.0 in 2021, then tumbled by 89.38% to $29000.0 in 2022, then skyrocketed by 162.07% to $76000.0 in 2023, then grew by 10.53% to $84000.0 in 2024, then increased by 16.67% to $98000.0 in 2025.
  • Business Quant data shows Revenue for VYNE at $98000.0 in Q2 2025, $202000.0 in Q1 2025, and $84000.0 in Q4 2024.